Spots Global Cancer Trial Database for binimetinib
Every month we try and update this database with for binimetinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) | NCT05564403 | Recurrent Bilia... Recurrent Dista... Recurrent Gallb... Recurrent Intra... Stage III Dista... Stage III Hilar... Stage III Intra... Stage IV Distal... Stage IV Hilar ... Stage IV Intrah... Unresectable Bi... Unresectable Di... Unresectable Ga... Unresectable In... | Binimetinib Biopsy Biospecimen Col... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Leucovorin Calc... Magnetic Resona... Multigated Acqu... Oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) | NCT04439344 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Binimetinib | 18 Years - | National Cancer Institute (NCI) | |
| Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma | NCT04598009 | Melanoma Stage ... Melanoma Stage ... | Binimetinib Imatinib | 18 Years - | University of California, San Francisco | |
| Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | NCT03475004 | Colorectal Canc... Metastatic Canc... | Pembrolizumab Bevacizumab Binimetinib | 18 Years - 99 Years | University of Colorado, Denver | |
| Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer | NCT02451865 | Recurrent Non-S... Stage IV Non-Sm... | Binimetinib Docetaxel Laboratory Biom... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | NCT04720976 | Solid Tumor NSCLC | JAB-3312 Binimetinib Pembrolizumab Sotorasib Osimertinib | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer | NCT04132505 | Metastatic Panc... Stage IV Pancre... | Binimetinib Hydroxychloroqu... | 18 Years - | M.D. Anderson Cancer Center | |
| ENCOrafenib With Binimetinib in bRAF NSCLC | NCT04526782 | Non Small Cell ... BRAF V600E | Encorafenib 75 ... Binimetinib 15 ... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors | NCT03864042 | Advanced Solid ... Metastatic Mela... | losartan dextromethorpha... caffeine omeprazole midazolam rosuvastatin bupropion immed... encorafenib binimetinib modafinil | 18 Years - | Pfizer | |
| Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | NCT02902042 | Malignant Melan... | Encorafenib Binimetinib Pembrolizumab Pembrolizumab a... | 18 Years - | University Hospital, Essen | |
| Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) | NCT04439344 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Binimetinib | 18 Years - | National Cancer Institute (NCI) | |
| Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | NCT02910700 | Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me... | Binimetinib Dabrafenib Encorafenib Laboratory Biom... Nivolumab Pharmacological... Trametinib | 18 Years - | M.D. Anderson Cancer Center | |
| Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | NCT02902042 | Malignant Melan... | Encorafenib Binimetinib Pembrolizumab Pembrolizumab a... | 18 Years - | University Hospital, Essen | |
| Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer | NCT04965818 | Advanced or Met... Non-Small Cell ... KRAS Gene Mutat... | Futibatinib and... | 18 Years - | Taiho Oncology, Inc. | |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | NCT04511013 | Acral Lentigino... Clinical Stage ... Metastatic Cuta... Metastatic Mali... Metastatic Mela... Metastatic Muco... Pathologic Stag... | Binimetinib Encorafenib Ipilimumab Nivolumab | 18 Years - | SWOG Cancer Research Network | |
| PF-07284892 in Participants With Advanced Solid Tumors | NCT04800822 | Solid Tumor | PF-07284892 lorlatinib binimetinib cetuximab encorafenib | 18 Years - | Pfizer | |
| A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement | NCT04543188 | Malignant Melan... Carcinoma, Non-... Brain Neoplasms... Brain Neoplasms Malignant Neopl... | PF-07284890 Binimetinib Midazolam | 16 Years - | Pfizer | |
| Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | NCT03475004 | Colorectal Canc... Metastatic Canc... | Pembrolizumab Bevacizumab Binimetinib | 18 Years - 99 Years | University of Colorado, Denver | |
| Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer | NCT03991819 | Non-small Cell ... | Binimetinib Pembrolizumab | 18 Years - | University Health Network, Toronto | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE | NCT04720768 | Melanoma Metastasis | Binimetinib Encorafenib Palbociclib | 18 Years - 100 Years | Peter MacCallum Cancer Centre, Australia | |
| Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement | NCT04221438 | Melanoma of Unk... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Cutan... | Binimetinib Computed Tomogr... Conventional Su... Encorafenib Fluorothymidine... Positron Emissi... | 18 Years - | Eastern Cooperative Oncology Group | |
| A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | NCT04913285 | Solid Tumor, Ad... Non-small Cell ... Melanoma | KIN-2787 KIN-2787 and bi... | 18 Years - | Pierre Fabre Medicament | |
| A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers | NCT03843775 | Advanced BRAF M... | Binimetinib Encorafenib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant | NCT04322383 | Hairy Cell Leuk... | binimetinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas | NCT03231306 | Neurofibromatos... Plexiform Neuro... | Binimetinib | 1 Year - | University of Alabama at Birmingham | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | NCT05564377 | Advanced Malign... Anatomic Stage ... Anatomic Stage ... Locally Advance... Malignant Femal... Metastatic HER2... Metastatic Mali... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Unresectable HE... Unresectable Ma... | Alpelisib Binimetinib Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Fulvestrant Ipatasertib Leucovorin Magnetic Resona... Multigated Acqu... Mutation Carrie... Neratinib Malea... Nilotinib Hydro... Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Positron Emissi... Selumetinib Sul... Sotorasib | - | National Cancer Institute (NCI) | |
| Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma | NCT05304546 | Malignant Melan... Metastatic Mela... Immunotherapy BRAF V600E Malignant Melan... | Pembrolizumab Encorafenib Binimetinib | 18 Years - | Sheba Medical Center | |
| Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement | NCT04221438 | Melanoma of Unk... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Cutan... | Binimetinib Computed Tomogr... Conventional Su... Encorafenib Fluorothymidine... Positron Emissi... | 18 Years - | Eastern Cooperative Oncology Group | |
| Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | NCT03106415 | Breast Adenocar... Metastatic Trip... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Binimetinib Laboratory Biom... Pembrolizumab | 18 Years - | Mayo Clinic | |
| Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer | NCT03693170 | BRAF V600E-muta... | encorafenib Binimetinib Cetuximab | 18 Years - | Pierre Fabre Medicament | |
| Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial | NCT05554367 | Malignant Solid... Ovarian Low Gra... Pancreatic Carc... Stage IV Ovaria... Stage IV Pancre... | Binimetinib Biopsy Biospecimen Col... Bone Scan Computed Tomogr... Magnetic Resona... Palbociclib | 18 Years - | National Cancer Institute (NCI) | |
| Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | NCT04061980 | BRAF NP_004324.... BRAF V600E Muta... Metastatic Thyr... Refractory Thyr... Stage IV Differ... Stage IVA Diffe... Stage IVB Diffe... | Binimetinib Encorafenib Nivolumab | 18 Years - | Providence Health & Services | |
| Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE | NCT04720768 | Melanoma Metastasis | Binimetinib Encorafenib Palbociclib | 18 Years - 100 Years | Peter MacCallum Cancer Centre, Australia | |
| Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer | NCT03981614 | Metastatic Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Ca... | Binimetinib Palbociclib Trifluridine an... | 18 Years - | Academic and Community Cancer Research United | |
| Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | NCT03543969 | Melanoma (Skin) Skin Cancer Skin Melanoma Skin Carcinoma | Encorafenib Binimetinib Nivolumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment | NCT04045691 | Melanoma Stage ... Melanoma Stage ... | Encorafenib Binimetinib | 18 Years - | Pierre Fabre Pharma GmbH | |
| Lorlatinib Combinations in Lung Cancer | NCT04292119 | Lung Cancer Anaplastic Lymp... ROS1 Rearrangem... Relapsed Cancer MET Amplificati... Resistant Cance... NSCLC | Lorlatinib Crizotinib Binimetinib TNO155 | 18 Years - | Massachusetts General Hospital | |
| Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations | NCT02263898 | Recurrent Melan... Stage IV Melano... | Raf kinase inhi... binimetinib laboratory biom... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations | NCT02263898 | Recurrent Melan... Stage IV Melano... | Raf kinase inhi... binimetinib laboratory biom... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation | NCT04390243 | Locally Advance... Metastatic Panc... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... | Binimetinib Encorafenib | 18 Years - | Academic and Community Cancer Research United | |
| Personalized Medicine for Advanced Biliary Cancer Patients | NCT05615818 | Biliary Tract N... | Futibatinib Ivosidenib Zanidatamab Trastuzumab Neratinib Encorafenib Binimetinib Niraparib Cisplatin Gemcitabine | 18 Years - | UNICANCER | |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
| Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation | NCT03271047 | MSS RAS-mutant Colo... | binimetinib nivolumab ipilimumab | 18 Years - | Pfizer | |
| Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | NCT04061980 | BRAF NP_004324.... BRAF V600E Muta... Metastatic Thyr... Refractory Thyr... Stage IV Differ... Stage IVA Diffe... Stage IVB Diffe... | Binimetinib Encorafenib Nivolumab | 18 Years - | Providence Health & Services | |
| Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651) | NCT03374254 | Metastatic Colo... | Pembrolizumab Binimetinib Oxaliplatin Leucovorin 5-Fluorouracil ... Irinotecan | 18 Years - | Merck Sharp & Dohme LLC | |
| Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL | NCT04324112 | Hairy Cell Leuk... | binimetinib Encorafenib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
| Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma | NCT04375527 | Clinical Stage ... Clinical Stage ... Locally Advance... Metastatic Cuta... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Cu... | Binimetinib Nivolumab Questionnaire A... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) | NCT05554354 | Anatomic Stage ... Metastatic HER2... Metastatic Horm... | Binimetinib Biopsy Biospecimen Col... Bone Scan Computed Tomogr... Echocardiograph... Fulvestrant Magnetic Resona... Multigated Acqu... | 18 Years - | National Cancer Institute (NCI) | |
| Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations | NCT03839342 | Solid Tumor | Binimetinib Encorafenib | 18 Years - | University Health Network, Toronto | |
| Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer | NCT04005144 | ALK Gene Rearra... Lung Non-Small ... Progressive Dis... ROS1 Gene Rearr... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Binimetinib Brigatinib | 18 Years - | University of California, San Francisco | |
| Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer | NCT03981614 | Metastatic Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Ca... | Binimetinib Palbociclib Trifluridine an... | 18 Years - | Academic and Community Cancer Research United | |
| Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer | NCT04132505 | Metastatic Panc... Stage IV Pancre... | Binimetinib Hydroxychloroqu... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | NCT05355701 | Melanoma Non-Small-Cell ... Thyroid Cancer Glioma | PF-07799933 binimetinib cetuximab | 16 Years - | Pfizer | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer | NCT05111561 | Advanced Malign... Metastatic Mali... Refractory Mali... Triple-Negative... Unresectable Ma... | BET Bromodomain... Binimetinib Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial | NCT05554367 | Malignant Solid... Ovarian Low Gra... Pancreatic Carc... Stage IV Ovaria... Stage IV Pancre... | Binimetinib Biopsy Biospecimen Col... Bone Scan Computed Tomogr... Magnetic Resona... Palbociclib | 18 Years - | National Cancer Institute (NCI) | |
| Study to Evaluate the Efficacy and Safety of Cetuximab in Combination With Encorafenib Plus Binimetinib as Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer | NCT06207656 | Colorectal Canc... | EBC | 18 Years - | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
| Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer | NCT04005144 | ALK Gene Rearra... Lung Non-Small ... Progressive Dis... ROS1 Gene Rearr... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Binimetinib Brigatinib | 18 Years - | University of California, San Francisco | |
| Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer | NCT04044430 | Metastatic Colo... Metastatic Colo... Metastatic Micr... Metastatic Rect... Stage III Colon... Stage III Color... Stage III Recta... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta... | Binimetinib Encorafenib Nivolumab Questionnaire A... | 18 Years - | University of California, San Francisco | |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | NCT03915951 | Non-small Cell ... | encorafenib binimetinib | 18 Years - | Pfizer | |
| Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma | NCT05304546 | Malignant Melan... Metastatic Mela... Immunotherapy BRAF V600E Malignant Melan... | Pembrolizumab Encorafenib Binimetinib | 18 Years - | Sheba Medical Center | |
| Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) | NCT05564403 | Recurrent Bilia... Recurrent Dista... Recurrent Gallb... Recurrent Intra... Stage III Dista... Stage III Hilar... Stage III Intra... Stage IV Distal... Stage IV Hilar ... Stage IV Intrah... Unresectable Bi... Unresectable Di... Unresectable Ga... Unresectable In... | Binimetinib Biopsy Biospecimen Col... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Leucovorin Calc... Magnetic Resona... Multigated Acqu... Oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC. | NCT02964689 | Advanced Non-sm... KRAS Gene Mutat... Lung Cancer | Binimetinib Pemetrexed Cisplatin | 18 Years - 75 Years | Swiss Group for Clinical Cancer Research | |
| Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US | NCT05260684 | Melanoma | Encorafenib Binimetinib Vemurafenib Cobimetinib Dabrafenib Trametinib | 18 Years - | Pfizer | |
| Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment | NCT04045691 | Melanoma Stage ... Melanoma Stage ... | Encorafenib Binimetinib | 18 Years - | Pierre Fabre Pharma GmbH | |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | NCT03971409 | Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Invasive Breast... Recurrent Breas... Triple-Negative... Unresectable Br... | Anti-OX40 Antib... Avelumab Binimetinib Utomilumab Liposomal Doxor... Sacituzumab Gov... | 18 Years - | University of California, San Francisco | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | NCT02465060 | Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ... | Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases | NCT05026983 | Clinical Stage ... Metastatic Mela... Pathologic Stag... | Binimetinib Encorafenib Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer | NCT04965818 | Advanced or Met... Non-Small Cell ... KRAS Gene Mutat... | Futibatinib and... | 18 Years - | Taiho Oncology, Inc. | |
| Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE | NCT04720768 | Melanoma Metastasis | Binimetinib Encorafenib Palbociclib | 18 Years - 100 Years | Peter MacCallum Cancer Centre, Australia | |
| BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) | NCT02834364 | Relapsed or Ref... Patients With B... | Encorafenib Binimetinib | 18 Years - | University of Heidelberg Medical Center | |
| Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer | NCT03693170 | BRAF V600E-muta... | encorafenib Binimetinib Cetuximab | 18 Years - | Pierre Fabre Medicament | |
| Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer | NCT03170206 | Lung Cancer | Binimetinib Palbociclib | 18 Years - | Dana-Farber Cancer Institute | |
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | NCT03947385 | Metastatic Uvea... Cutaneous Melan... Colorectal Canc... Other Solid Tum... | IDE196 Binimetinib Crizotinib | 18 Years - | IDEAYA Biosciences | |
| A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung | NCT02185690 | Lungcancer | Binimetinib Pemetrexed Carboplatin | 18 Years - 90 Years | University Health Network, Toronto | |
| Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) | NCT04585815 | Carcinoma, Non-... | Sasanlimab Pref... Encorafenib Binimetinib Sasanlimab Axitinib SEA-TGT | 18 Years - | Pfizer | |
| Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | NCT03106415 | Breast Adenocar... Metastatic Trip... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Binimetinib Laboratory Biom... Pembrolizumab | 18 Years - | Mayo Clinic |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
